In this study, we investigated how gefitinib (ZD1839, Iressa®), an orally given, small-molecular EGFR tyrosine kinase inhibitor that is currently used in the clinic for NSCLC patients [15], can radiosensitize NSCLC cells in order to understand its mechanism of interaction with IR. Here, EGFR is linked to non-small cell lung carcinoma.